Suppr超能文献

髓系肉瘤:临床表现、诊断与治疗

Myeloid Sarcoma: Presentation, Diagnosis, and Treatment.

作者信息

Almond L Max, Charalampakis Maria, Ford Samuel J, Gourevitch David, Desai Anant

机构信息

Midlands Abdominal and Retroperitoneal Sarcoma Unit (MARSU), University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.

Department of Haematology and Stem Cell Transplantation, Heart of England NHS Foundation Trust, Birmingham, United Kingdom.

出版信息

Clin Lymphoma Myeloma Leuk. 2017 May;17(5):263-267. doi: 10.1016/j.clml.2017.02.027. Epub 2017 Mar 7.

Abstract

Myeloid sarcoma is an extramedullary tumor of immature granulocytic cells. It is a rare condition, most often associated with acute myeloid leukemia (AML), although in some rare cases it may present in nonleukemic patients. It should therefore be considered as a differential diagnosis of any atypical cellular infiltrate. It may occur at any site, leading to very varied clinical presentations. Diagnosis is challenging and relies on a high index of suspicion as well as radiology, histology, immunophenotyping, and molecular analyses, which also are essential for risk stratification and treatment planning. Systemic chemotherapy using AML-like regimens should be commenced early, even in nonleukemic disease. Surgery and/or radiotherapy may be indicated for symptomatic lesions or tumors causing local organ dysfunction or obstruction. Allogeneic hematopoietic stem cell transplantation has demonstrated promising results, particularly in patients who achieved complete remission with AML-induction protocols, and recent advances in genetic profiling may enable the development of novel targeted therapies. Prospective multicenter controlled trials are required to further refine management decisions and investigate the role of novel targeted therapies.

摘要

髓系肉瘤是一种由未成熟粒细胞构成的髓外肿瘤。它是一种罕见疾病,最常与急性髓系白血病(AML)相关,不过在一些罕见情况下也可能出现在非白血病患者中。因此,对于任何非典型细胞浸润都应将其视为鉴别诊断对象。它可发生于任何部位,导致临床表现千差万别。诊断具有挑战性,依赖于高度的怀疑指数以及放射学、组织学、免疫表型分析和分子分析,这些对于风险分层和治疗规划也至关重要。即使对于非白血病性疾病,也应尽早开始使用类似AML方案的全身化疗。对于有症状的病变或导致局部器官功能障碍或梗阻的肿瘤,可能需要进行手术和/或放疗。异基因造血干细胞移植已显示出有前景的结果,特别是在那些通过AML诱导方案实现完全缓解的患者中,并且基因谱分析的最新进展可能会推动新型靶向治疗的发展。需要进行前瞻性多中心对照试验,以进一步完善管理决策并研究新型靶向治疗的作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验